On this page
What each program costs in Nebraska
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does Nebraska Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Nebraska Medicaid's prior authorization forms cover Wegovy for heart risk or a liver condition and Zepbound only for sleep apnea, so neither form offers a path for weight loss alone. Read from state documents Nov 6, 2026.
What Nebraska Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Nebraska Department of Health and Human Services, Medicaid pharmacy program (Prime Therapeutics).
WegovyNo
Covered for heart event risk reduction in adults 45 to 74, or a liver condition (MASH) in adults 18 and older. Prior authorization required.
“Semaglutide (Wegovy) is covered for the reduction of the risk of major adverse cardiovascular events (MACE)”
Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions · No effective date on the document · read Nov 6, 2026
ZepboundNo
Only covered for moderate to severe sleep apnea in adults 18 and older. Prior authorization required.
“Tirzepatide (Zepbound) is only covered for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults aged at least 18 years.”
Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions · No effective date on the document · read Nov 6, 2026
OzempicNo
Preferred drug in the diabetes class. Requires a type 2 diabetes diagnosis, with a metformin trial or heart disease tied to diabetes.
“Preferred agents require a diagnosis of Type II diabetes AND a trial and failure or intolerance to metformin”
Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions · No effective date on the document · read Nov 6, 2026
MounjaroNo
Non-preferred drug in the diabetes class. Requires a diabetes diagnosis and trials of two preferred drugs.
“Diagnosis of diabetes with HbA1C ≥ 7 AND”
Nebraska DHHS Medicaid, via Prime Therapeutics State Government Solutions · No effective date on the document · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Nebraska Department of Health and Human Services, Medicaid pharmacy program (Prime Therapeutics) documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
471 prescriptions
Ozempic and Mounjaro, 2025
29,264 prescriptions
Neighbours covering weight loss
2 of 6
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Nebraska Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Nebraska Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Nebraska Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Nebraska Medicaid pay for?
37,324 GLP-1 prescriptions in 2025, 40th of the 50 states and DC, with $35.6 million reimbursed before rebates. Counting the share other payers covered, $36.1 million.
Prescriptions, 2025
37,324
40th of 51
Medicaid paid
$35.6M
40th of 51, before rebates
Per prescription
$954
$1,051 nationally
Weight-loss brands
1.3%
36th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Nebraska is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 1.3% of Nebraska Medicaid's GLP-1 prescriptions in 2025 (471). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Nebraska Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 23,578 | 63% | $22.5 million | $954 |
| Trulicity | 6,809 | 18% | $6.5 million | $958 |
| Mounjaro | 5,686 | 15% | $5.5 million | $966 |
| Rybelsus | 462 | 1.2% | $407,277 | $882 |
| Zepboundapproved for weight management | 355 | 1.0% | $362,140 | $1,020 |
| Victoza | 199 | 0.5% | $121,302 | $610 |
| Wegovyapproved for weight management | 116 | 0.3% | $149,230 | $1,286 |
| Liraglutide (generic) | 100 | 0.3% | $40,889 | $409 |
| Bydureon | 19 | 0.1% | $14,875 | $783 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Nebraska?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 1 in Nebraska. The register does not say which, if any, supplies a program on this page.
- Staska Pharmaceuticals, Inc., Bennet. Registered since Dec 3, 2020; last FDA inspection Feb 20, 2026.
On Medicare in Nebraska?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Nebraska and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
2 of the 6 states next to Nebraska cover GLP-1s for weight loss through Medicaid: Kansas and Missouri. None has a lower cash floor than Nebraska's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Nebraska | Not covered | 19 | $39/mo |
| Colorado | Not covered | 19 | $39/moWellmedr |
| Iowa | Not covered | 19 | $39/moWellmedr |
| Kansas | Covered | 19 | $39/moWellmedr |
| Missouri | Zepbound only | 18 | $39/moWellmedr |
| South Dakota | Not covered | 19 | $39/moWellmedr |
| Wyoming | Not covered | 19 | $39/moWellmedr |






















